

# Beta-binomial-models that respect randomization for meta-analysis of the odds ratio in case of very few events

Tim Mathes

Symposium “Recent Advances in Meta-Analysis” 29. August 2024

# Introduction

- Standard beta-binomial (BB) model has shown good statistical properties for meta-analyses of binary outcomes, in challenging situations with a low number of studies or (very) few events [1, 2,3,4]
- However it ignores the randomisation level (arm-based)
- **Aim:** To introduce BB models that respect randomization and compare these models in a simulation study in case of (very) few events

# Standard (common-*rho*) beta-binomial model (**BBST**)


- $E(\pi_i) = \mu_i = \alpha / (\alpha + \beta)$
  - $\text{Var}(\pi_i) = \mu_i(1 - \mu_i) \vartheta / (1 + \vartheta)$ , where  $\vartheta = 1 / (\alpha + \beta)$
  - Assumption correlation equal between study groups,  $\text{corr}(z_{ij}, z_{ik}) = \rho = 1 / (\alpha + \beta + 1)$ , is the same for all observations
- $(\alpha_C + \beta_C) = (\alpha + \beta) = (\alpha_T + \beta_T)$

# BBST estimation of treatment effect

- The treatment effect  $\theta = b_T = g^{-1}(\mu_T)/g^{-1}(\mu_C)$  is modelled via the link function
$$g(\mu_i) = b_0 + b_T \times i$$

→ ignores the randomization level

# Common-*beta* beta-binomial model (BBCB)



- Alternative assumption is that  $\beta$  is the same across studies/groups, so that  $\beta_C = \beta_T = \beta$  but the alphas ( $\alpha_C$ , and  $\alpha_T$ ) differ between studies/groups

# Common-*beta* beta-binomial model

The Stata Journal (2005)  
5, Number 3, pp. 385–394

## A simple approach to fit the beta-binomial model

Paulo Guimarães

- Suppose a fixed-effects negative binomial regression (FE-NegBin) with response  $y$ , an intercept  $c_0$ , a binary indicator  $c_1$ , and the interaction of  $c_1$  and the treatment effect  $c_T$
- If we set  $\beta = \exp(c_0)$ ,  $\alpha_T = \exp(c_0 + c_1 + c_T)$ , and  $\alpha_C = \exp(c_0 + c_1)$ , then the likelihood of the common-*beta* FE-NegBin and the common-*beta* BB coincide, if the FE-NegBin is estimated by conditional maximum likelihood [5]

# Estimating CBBBs using panel count data models

The ML estimation can be conditioned on the counts in each study\_group (ignores randomization) [6] or each study (respects randomisation)

Study	Treatment	Study Group	Success	$y$	BBCB_ignor	BBCN_resp	BBST
1	1	1	1	16	} $\Sigma$	} $\Sigma$	} $\Sigma$
1	1	1	0	8			
1	0	2	1	17	} $\Sigma$	} $\Sigma$	} $\Sigma$
1	0	2	0	11			
2	1	3	1	12	} $\Sigma$	} $\Sigma$	} $\Sigma$
2	1	3	0	0			
2	0	4	1	7	} $\Sigma$	} $\Sigma$	} $\Sigma$
2	0	4	0	3			

# Simulation setup

- Design factors based on real-world meta-analyses [7, 8]
- Mirrors non-Cochrane (median number of studies=8) and Cochrane (median number of studies=3) meta-analyses
- Median **odds ratio (OR)** under  $H_1=0.69$
- Event probabilities: 0.01; 0.02; 0.05
- Data were generate from an inverse variance model
- 10,000 meta-analyses
  
- Results are only presented for  $H_1$




# Comparator models

- Generalized linear mixed model with a random intercept and random treatment effect (**GLRR**) [9]:  $g(\pi_{ki}) = \gamma_k + i \times \theta + i \times \epsilon_k$
- Inverse variance random-effects model
  - Heterogeneity variance estimated using the Paule-Mandel method
    - Hartung-Knapp-Sidik-Jonkman 95%CI's (**HKPM**)
    - Refined version of Hartung-Knapp-Sidik-Jonkman 95%CI's (**MHKPM**): variance correction is only applied if the 95%CI's of the original HKSJ-method are smaller than the Wald-type 95%CI's


# Bias

model    □ BBCB1    □ BBST    □ HKPM  
          □ BBCB2    □ GLRR    □ MHKPM




# Coverage

model  
BBCB1    BBST    HKPM  
BBCB2    GLRR    MHKPM




# Power

model  
BBCB1   BBST   HKPM  
BBCB2   GLRR   MHKPM



# Agreement of treatment effect

- In situations where models disagreed ORs were often unrealistic high in consideration of the data
- BBCB\_resp tends to show implausible results when sample sizes between studies varied strongly
- BBCB\_ignor tends to show implausible results when there was (very) large heterogeneity



# Conclusion

- Theoretical advantage: no continuity correction is necessary and never falls back to a fixed-effect model
- The preliminary results of this simulation study indicate that the BBCB respecting randomization might be a promising candidate for pooling studies in the case of very rare events
- The BBCBs have a closed-form and can be conveniently implemented using standard procedures from statistical software as used in econometrics (e.g. PROC COUNTREG SAS, plm package in R, xtnbreg in Stata)
- The idea of using panel count data estimation routines opens the door for using any panel data model that has been introduced previously, e.g. zero inflated Poisson-regression, random-effects negative binomial regression

# References

1. Beisemann, M., Doebler, P., & Holling, H. (2020). Comparison of random-effects meta-analysis models for the relative risk in the case of rare events: A simulation study. *Biometrical Journal*, 62(7), 1597-1630.
2. Jansen, K., & Holling, H. (2023). Random-effects meta-analysis models for the odds ratio in the case of rare events under different data-generating models: A simulation study. *Biometrical Journal*, 65(3), 2200132.
3. Kuss O. Statistical methods for meta-analyses including information from studies without any events—add nothing to nothing and succeed nevertheless. *Statistics in Medicine*. 2015;34(7):1097-1116.
4. Mathes T, Kuss O. A comparison of methods for meta-analysis of a small number of studies with binary outcomes. *Res Synth Methods*. 2018;9(3):366-81.
5. Guimaraes, P. (2005). A simple approach to fit the beta-binomial model. *The Stata Journal*, 5(3), 385-394.
6. Mathes, T. and O. Kuss, Beta-binomial models for meta-analysis with binary outcomes: Variations, extensions, and additional insights from econometrics. *Research Methods in Medicine & Health Sciences*, 2021: p. 2632084321996225.
7. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al. Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. *PLOS Medicine*. 2016;13(5):e1002028.
8. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JPT. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *International journal of epidemiology*. 2012;41(3):818-27.
9. Jackson D, et al. A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio. *Statistics in medicine*, 2018, 37. Jg., Nr. 7, S. 1059-1085.

# Description simulation study

Parameter	Distributional assumption and parameter specification	Description of resulting data set
Sample size of single study $n_k$	Generated from a log-normal distribution with $\mu_{ND} = 4.615$ and $\sigma_{ND} = 1.1$	Q1 = 50.0, median = 102.0, mean = 185.7, Q3 = 213.0
Sample size of treatment (control) arm of single study $n_{kT}$ ( $n_{kC}$ )	For $n_{kT}$ : Generated from a binomial distribution with event probability 0.5 (1:1 randomisation) and $n_k$ as number of experiments For $n_{kC}$ : $n_k - n_{kT}$	Based on Fleishman power transformation
Event probability in control group $\pi_{C,true}$	Generated from a beta distribution with $\alpha = 0.42$ and $\beta = 1.43$	Q1 = 0.024, median = 0.129, mean = 0.230, Q3 = 0.369
Variation $\sigma^2$ within study	Is implicitly given by random sample size of single study and event probability in control group	
Heterogeneity $\tau^2$ between the studies (for $\theta = \log OR$ )	Generated from a log normal distribution with $\mu_{ND} = -1.47$ , $\sigma_{ND} = 1.65$ and skewness = $-0.55$ using Fleishman's power transformation to generate the skewed distribution[44, 45]	$\tau^2$ : Q1 = 0.079, median = 0.273, mean = 0.621, Q3 = 0.802
Effect size of $\theta = \log OR$ under $H_1$	Generated from a log normal distribution with $\mu_{ND} = -0.59$ , $\sigma_{ND} = 0.61$ , skewness = $-1.28$ and kurtosis = 3.68	OR: Q1 = 0.527, mean = 0.673, median = 0.694, Q3 = 0.838
OR: odds ratio; SD: standard deviation; Q1: 1st quartile; Q3: 3rd quartile		



# Number of zero studies

Scenario			Proportion of zero studies			
Number of studies in meta-analysis	Effect	Baseline probability in the control arm	Proportion of zero studies in treatment arm	Proportion of zero studies in control arm	Proportion of single zero studies in either control or treatment arm	Proportion of double zero studies
"CO"	"H0"	0.01	0.54	0.55	0.73	0.36
"CO"	"H0"	0.02	0.38	0.37	0.55	0.2
"CO"	"H0"	0.05	0.19	0.17	0.29	0.06
"CO"	"H1"	0.01	0.62	0.55	0.77	0.4
"CO"	"H1"	0.02	0.47	0.37	0.61	0.24
"CO"	"H1"	0.05	0.26	0.16	0.35	0.08
"NC"	"H0"	0.01	0.54	0.55	0.73	0.36
"NC"	"H0"	0.02	0.38	0.37	0.55	0.2
"NC"	"H0"	0.05	0.19	0.16	0.29	0.06
"NC"	"H1"	0.01	0.62	0.55	0.77	0.4
"NC"	"H1"	0.02	0.47	0.37	0.6	0.24
"NC"	"H1"	0.05	0.27	0.16	0.35	0.08